Rituximab with high‐dose methotrexate in primary central nervous system lymphoma
暂无分享,去创建一个
L. Sehn | J. Connors | K. Savage | T. Shenkier | D. Villa | A. Gerrie | R. Kansara
[1] F. Cavalli,et al. Addition of Thiotepa and Rituximab to Antimetabolites Significantly Improves Outcome in Primary CNS Lymphoma: First Randomization of the IELSG32 Trial. , 2015, Clinical advances in hematology & oncology : H&O.
[2] D. Correa,et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. , 2015, Blood.
[3] M. Chamberlain. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma , 2015, Neurology.
[4] A. Brandes,et al. MATILDE chemotherapy regimen for primary CNS lymphoma , 2014, Neurology.
[5] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[6] D. Correa,et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] P. Treseler,et al. How I treat CNS lymphomas. , 2013, Blood.
[8] S. Opat,et al. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. , 2013, Neuro-oncology.
[9] B. Cheson,et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Straube,et al. Rituximab significantly improves complete response rate in patients with primary CNS lymphoma , 2012, Journal of Neuro-Oncology.
[11] C. Kruchko,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. , 2012, Neuro-oncology.
[12] A. López-Guillermo,et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. , 2011, The Lancet. Oncology.
[13] T. Mikkelsen,et al. Rituximab monotherapy for patients with recurrent primary CNS lymphoma , 2011, Neurology.
[14] E. Thiel,et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. , 2010, The Lancet. Oncology.
[15] B. Coiffier,et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.
[16] J. Blay,et al. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] K. Hynynen,et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Fridlyand,et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Randy D Gascoyne,et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Stephen L. Brown,et al. Model Selection in Magnetic Resonance Imaging Measurements of Vascular Permeability: Gadomer in a 9L Model of Rat Cerebral Tumor , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[21] J. O'Brien,et al. Pathology and genetics of primary central nervous system and intraocular lymphoma. , 2005, Hematology/oncology clinics of North America.
[22] H. Karnath,et al. NOA‐03 trial of high‐dose methotrexate in primary central nervous system lymphoma: Final report , 2005, Annals of neurology.
[23] R. Gascoyne,et al. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients , 2005, Cancer.
[24] R. Fimmers,et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] T. Batchelor,et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Blay,et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] K. Aldape,et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. , 2003, Blood.
[28] L. Deangelis,et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] L. Deangelis,et al. Treatment for primary CNS lymphoma: the next step. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D. Nelson,et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. , 1992, International journal of radiation oncology, biology, physics.